DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics ...
Iterum Therapeutics plc announced the publication of results from its Phase 3 clinical trial, REASSURE, in NEJM Evidence, which evaluated the efficacy of oral sulopenem compared to Augmentin® in ...
DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the "Company” or "Iterum” or "we”), a company focused on delivering next generation oral and IV ...
Iterum Therapeutics plc announced that it has partnered with EVERSANA Life Science Services to commercialize its approved product, ORLYNVAHTM, the first oral penem antibiotic in the U.S., aiming for a ...
Industry Veteran To Lead Commercialization of Potential New Oral and IV Antibiotic DUBLIN and CHICAGO, Feb. 20, 2018 /PRNewswire/ -- Iterum Therapeutics Limited, a clinical-stage pharmaceutical ...
Iterum Therapeutics PLC (NASDAQ:ITRM) shares are trending Tuesday after the company announced its Phase 3 Reassure trial met the primary endpoint of non-inferiority to Augmentin. “We are very pleased ...
DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by ...
DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results